Prospective Clinical Evaluation of the FilmArray® NGDS Warrior Panel

NCT ID: NCT02547636

Last Updated: 2016-12-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1822 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-12-31

Study Completion Date

2016-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will evaluate the clinical specificity of the FilmArray NGDS Warrior Panel.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Evaluation of Test Panel

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Subjects/specimens that meet the inclusion criteria

Subjects/specimens that meet the inclusion criteria

Observational study

Intervention Type OTHER

No intervention will be used in this study.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Observational study

No intervention will be used in this study.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Whole blood (prospectively collected via informed consent):
* Adult subject has a recorded or self-reported fever within the previous 24 hours
* Subject provides informed consent prior to enrollment and specimen collection
* Subject has not previously provided a whole blood specimen for this study

Whole blood (residual)

* Whole blood (in EDTA) submitted to laboratory for standard of care testing
* Specimen is not from an individual with a specimen previously enrolled in the study

Positive Blood Culture:

* Culture was detected as positive by an automated blood culture system
* Culture is not from a patient previously enrolled in the study

Negative Blood Culture:

* Culture not detected as positive by an automated blood culture system
* Culture is not from a patient previously enrolled in the study

Sputum:

* Specimen was accepted for testing by the respective site's microbiology laboratory
* Specimen is not from an individual that has a sputum already enrolled in the study
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

BioFire Defense LLC

INDUSTRY

Sponsor Role collaborator

BioFire Diagnostics, LLC

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Navy Medical Center San Diego/Naval Health Research Center

San Diego, California, United States

Site Status

Tripler Army Medical Center

Honolulu, Hawaii, United States

Site Status

Washington University/Barnes Jewish Hospital

St Louis, Missouri, United States

Site Status

University of Nebraska Medical Center

Omaha, Nebraska, United States

Site Status

Ohio State University Medical Center

Columbus, Ohio, United States

Site Status

Madigan Army Medical Center

Tacoma, Washington, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

DX-SDY-020450

Identifier Type: -

Identifier Source: org_study_id